pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Apr 27·1 min read
save

Insider explains the true purpose behind prior authorizations in U.S. health insurance

Apr 27, 2026·read at STAT ↗Neutral

The STAT+ newsletter article by Bob Herman reports on an interview with Archelle Georgiou, who previously worked at the nation’s largest health insurer and was involved in efforts to curb prior authorization requirements.

Georgiou explains that prior authorizations are less about clinical safety and more about controlling costs and managing utilization, describing how the process often results in denied claims as an intended outcome.

The piece highlights ongoing frustration among patients and providers with the system and suggests that the practice persists because it serves financial objectives for insurers rather than improving care quality.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: An insider reveals the real goals of prior authorization”

read at STAT ↗
466 words · retrieved Apr 27
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Sanofi2ASTELLASDare Bioscience, Inc.
topics
Gene Therapy (AAV)Psychiatry & CNS

related stories

  • Apr 27STAT+: Astellas retries XLMTM gene therapy after deathsSTAT
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • Apr 27STAT+: Erasca touts strong, though preliminary, results in trial of pancreatic and lung cancer therapySTAT
  • Apr 27STAT+: Zap in a cap: How one neurotech startup is using a hat to treat depressionSTAT
  • Apr 24STAT+: Sanofi MS drug gets positive review in Europe following FDASTAT